By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Vallongatan 1

Uppsala    SE-752 28  Sweden
Phone: 46-18-50-54-40 Fax: 46-18-51-08-73



Company News
Sales Focus For Oasmia 6/8/2016 10:54:37 AM
Oasmia Touts Positive Paclical/Apealea Phase III Data; NDA Being Readied for U.S. 4/27/2016 7:09:38 AM
Oasmia Reports Positive Clinical Study Results For Proprietary XR17 Nanotechnology 4/5/2016 1:37:28 PM
Oasmia Announces Enrollment Of First Patient In Clinical Study With Docecal, A Novel Formulation Of Docetaxel 3/30/2016 9:09:52 AM
Oasmia: Interviewed By NyhetsbyrÄn Direkt 3/24/2016 10:07:45 AM
Oasmia Release: OASM Advances Global Commercialization Efforts For All Products 2/25/2016 9:02:27 AM
Oasmia Has Submitted A Marketing Authorization Application To The European Medicines Agency For Its Lead Cancer Product Apealea (Paclical) 2/8/2016 6:18:44 AM
Oasmia Makes Key Hires; Strengthens Organizational Structure Entering Commercial Phase 2/3/2016 6:42:16 PM
Oasmia Receives Order Of $7.5 Million In End-User Value For The Russian Market 10/30/2015 6:48:49 AM
Oasmia Announces Pricing Of Public Offering Of American Depositary Shares And NASDAQ Listing 10/29/2015 12:48:03 PM